Kohles JD - Search Results

1

Patterns of bisphosphonate use in the United States in the treatment of metastatic bone disease.

Mortimer JE, Schulman K, Kohles JD. Mortimer JE, et al. Among authors: kohles jd. Clin Breast Cancer. 2007 Aug;7(9):682-9. doi: 10.3816/CBC.2007.n.027. Clin Breast Cancer. 2007. PMID: 17919348

2

Economic burden of metastatic bone disease in the U.S.

Schulman KL, Kohles J. Schulman KL, et al. Cancer. 2007 Jun 1;109(11):2334-42. doi: 10.1002/cncr.22678. Cancer. 2007. PMID: 17450591 Free article.

3

Cost comparison of capecitabine in patients with breast cancer.

Rugo HS, Kohles J, Schulman KL. Rugo HS, et al. Am J Clin Oncol. 2010 Dec;33(6):550-6. doi: 10.1097/COC.0b013e3181c06f94. Am J Clin Oncol. 2010. PMID: 20051811

4

Patient satisfaction in postmenopausal women treated with a weekly bisphosphonate transitioned to once-monthly ibandronate.

Bonnick SL, Silverman S, Tanner SB, Martens M, Bachmann G, Kohles JD, Civitelli R. Bonnick SL, et al. Among authors: kohles jd. J Womens Health (Larchmt). 2009 Jul;18(7):935-43. doi: 10.1089/jwh.2008.1064. J Womens Health (Larchmt). 2009. PMID: 19563245

5

Association of age and overall survival in capecitabine-treated patients with metastatic breast cancer in clinical trials.

Blum JL, Kohles J, McKenna E, Scotto N, Hu S, Odom D, Kaye JA, Glück S. Blum JL, et al. Breast Cancer Res Treat. 2011 Jan;125(2):431-9. doi: 10.1007/s10549-010-1222-3. Epub 2010 Nov 3. Breast Cancer Res Treat. 2011. PMID: 21042933

6

Gastrointestinal tolerability with ibandronate after previous weekly bisphosphonate treatment.

Derman R, Kohles JD, Babbitt A. Derman R, et al. Among authors: kohles jd. Clin Interv Aging. 2009;4:357-65. doi: 10.2147/cia.s5637. Epub 2009 Oct 12. Clin Interv Aging. 2009. PMID: 19851511 Free PMC article.

7

Rapid suppression of bone resorption marker levels with ibandronate therapy in a bisphosphonate-naïve population.

Sebba AI, Broy S, Kohles JD, Weissman P. Sebba AI, et al. Among authors: kohles jd. J Clin Densitom. 2008 Jul-Sep;11(3):417-23. doi: 10.1016/j.jocd.2008.02.004. Epub 2008 May 5. J Clin Densitom. 2008. PMID: 18456528

8

Monthly ibandronate suppresses serum CTX-I within 3 days and maintains a monthly fluctuating pattern of suppression.

Binkley N, Silverman SL, Simonelli C, Santiago N, Kohles JD, Dasic G, Sunyecz JA. Binkley N, et al. Among authors: kohles jd. Osteoporos Int. 2009 Sep;20(9):1595-601. doi: 10.1007/s00198-008-0827-4. Epub 2009 Jan 15. Osteoporos Int. 2009. PMID: 19145396 Clinical Trial.

9

In vivo activity of novel capecitabine regimens alone and with bevacizumab and oxaliplatin in colorectal cancer xenograft models.

Kolinsky K, Shen BQ, Zhang YE, Kohles J, Dugan U, Zioncheck TF, Heimbrook D, Packman K, Higgins B. Kolinsky K, et al. Mol Cancer Ther. 2009 Jan;8(1):75-82. doi: 10.1158/1535-7163.MCT-08-0596. Mol Cancer Ther. 2009. PMID: 19139115

10

Improved GI tolerability with monthly ibandronate in women previously using weekly bisphosphonates.

Binkley N, Martens MG, Silverman SL, Derman RJ, Greenwald M, Kohles JD, Bachmann GA. Binkley N, et al. Among authors: kohles jd. South Med J. 2009 May;102(5):486-92. doi: 10.1097/SMJ.0b013e31819ed0dd. South Med J. 2009. PMID: 19373149 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

19 results

Search Page

Filters